Most Read Brexit Articles of 2019

Three years on from the UK’s decision to leave the European Union, Brexit continued to dominate the headlines.  2019 brought many changes, including a new occupant at Number 10 Downing Street, a prorogued parliament and a constitutional crisis.  As usual, we provided comprehensive coverage of Brexit and its implications for companies in the life science sector.  Here, we are highlighting the most read and shared Brexit articles from our website in the past 12 months.

The UK PSMF – What Will It Look Like?

How will the Pharmacovigilance System Master File (PSMF) be impacted by the UK’s departure from the EU?  What actions will companies with a UK Marketing Authorisation Holder (MAH)  need to take in the event of a no-deal Brexit? In this short article, we consider the questions and give advice on what you need to consider and what you need to do, if you are impacted. Read the full article here.

What Will Happen To The QPPV Post Brexit?

Brexit will impact on many aspects of the life sciences sector.  One of the areas that will be most impacted will be the role of the Qualified Person for Pharmacovigilance (the QPPV).  In this article, we consider the impact that the UK’s exit from the EU will have on the role and the measures that companies will need to take once Brexit happens. Read more here.

Will Clinical Trials Be Impacted By Brexit?

How will clinical trials be impacted by the UK’s decision to leave the European Union?

The United Kingdom’s decision to leave the European Union (EU) will present significant implications to the pharmaceutical industry. Clinical trial sponsors and associated partners should be prepared for a variety of scenarios arising from Brexit which could impact on the manufacturing, licensing and distribution of health products between Ireland and the UK. Read the full article here.

Impact of No-Deal Brexit on Medical Devices

The currently expected Brexit day of October 31st 2019 is approaching and with a no-deal or cliff edge Brexit a very real possibility, there are several key areas for medical device companies to consider in terms of impact to their business in the event of a no-deal Brexit scenario. We wish to highlight here two areas for consideration for the medical devices sector.  Read the full article here.

Stay up to date with all of the latest news and articles from the team at Acorn Regulatory by subscribing to our monthly newsletter.  Subscribe by completing the form below.